MBRX - モレキュリン・バイオテック (Moleculin Biotech Inc.) モレキュリン・バイオテック

 MBRXのチャート


 MBRXの企業情報

symbol MBRx
会社名 Moleculin Biotech Inc (モレキュリン・バイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Moleculin Biotech Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin which it refers to as Annamycin an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress one involving a portfolio of small molecules which it refers to as the WP1066 Portfolio focused on the modulation of key oncogenic transcription factors involved in the progression of cancer and the WP1122 Portfolio a suite of molecules targeting the metabolic processes involved in cancer in general and glioblastoma. As of April 3 2017 it had not generated any revenue from its operations.   モレキュリン・バイオテックは米国のバイオ医薬品企業。臨床前と臨床段階において、がん治療薬の開発に焦点を当て、テキサス大学システムのMDアンダ―ソン・がんセンタ―とのライセンス契約に基づく。同社候補薬は「リボソ―ム型Annamycin」で、抵抗性急性脊髄性白血病の治療を目指す。本社はテキサス州ヒュ―ストン。   Moleculin Biotech Inc is a clinical-stage pharmaceutical company. The company is engaged in the development of anti-cancer drug candidates. Its drug development technologies include liposomal Annamycin, WP1122 and WP1066.
本社所在地 5300 Memorial Drive Suite 950 Houston TX 77007 USA
代表者氏名
代表者役職名
電話番号 +1 713-300-5160
設立年月日 42186
市場名 NASDAQ Small Cap
ipoyear 2016年
従業員数
url www.moleculin.com
nasdaq_url https://www.nasdaq.com/symbol/mbrx
adr_tso
EBITDA EBITDA(百万ドル) -13.86700
終値(lastsale) 1.41
時価総額(marketcap) 37874710.77
時価総額 時価総額(百万ドル) 32.50241
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 20.78041
当期純利益 当期純利益(百万ドル) -13.10300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Moleculin Biotech Inc revenues was not reported. Net loss increased 88% to $7.1M. Higher net loss reflects Research and development increase from $1.2M to $5.5M (expense) Gain from expiration of warrants decrease of 55% to $1M (income) General and administrative increase of 58% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.21 to -$0.28.

 MBRXのテクニカル分析


 MBRXのニュース

   Soliton: A Reg A+, PR Machine With Lockup Expiry Next Week - $6 2-Week Price Target  2019-05-16
Soliton ( SOLY ) had a recent Reg A+ IPO in February 2019, with an unproven device that is supposed to assist a laser with tattoo and cellulite removal. SOLY is a relentless PR machine that we believe will end very badly for shareholders who think they are holding a solid investment. The compa…
   PRPO, MBRX among premarket gainers  2019-04-29
Precipio (NASDAQ: PRPO ) +38% on first major international services contract. More news on: Precipio, Inc., Innovate Biopharmaceuticals, Inc., Changyou.com Limited, Stocks on the move, Read more …
   Generex Biotechnology Announces Organizational Roadmap & Investor Conference Call: Update on Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans  2019-04-29 PR Newswire
MIRAMAR, Florida , April 29, 2019 /PRNewswire/ -- Launch of Excellagenfor Wound Healing by subsidiary Olaregen Therapeutix Pending completion of acquisitions: Pantheon Medical, MediSource Partners, and Fuse Medical, Financing initiatives S1 Filing Applicati…
   Positive Results From HMN Lithium Project P.E.A.  2019-04-29 PR Newswire
VANCOUVER, British Columbia , April 29, 2019 /PRNewswire/ -- Highlights US$217 million ( Cdn$290 million ) after-tax Net Present Value at 8% discount rate and Internal Rate of Return of 28.0%; PEA based on a production rate of 5,000 tonnes of lithium carbonate…
   US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment  2019-04-29 PR Newswire
HOUSTON , April 29, 2019 /PRNewswire/ --A small public company with 6 highly promising anti-cancer drugs in the pipeline is augmenting US clinical trials with trials in Poland , speeding the process of patient recruitment and data collection. The company, Moleculin (NASDAQ: MBRX), …
   XLNX, BCOV, VC and TZOO among midday movers  2019-04-25
Gainers: Tiziana Life Sciences (NASDAQ: TLSA ) +35% . Appliance Recycling Centers of America (NASDAQ: ARCI ) +24% . Travelzoo (NASDAQ: TZOO ) +18% . Socket Mobile (NASDAQ: SCKT ) +16% . AXT (NASDAQ: AXTI ) +15% . Atossa Genetics (NASDAQ: ATOS ) +12% . Brightcove (NASDAQ: BCOV )…
   NOK, XLNX and MMM among premarket losers  2019-04-25
Consolidated Communications CNSL -26% on Q1 earnings . More news on: Moleculin Biotech, Inc., Huami Corporation, Midatech Pharma Plc, Stocks on the move, , Read more …

 関連キーワード  (医薬品 米国株 モレキュリン・バイオテック MBRX Moleculin Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)